SAVA
Cassava Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.32
+2.33%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.86x
- Price / sales
- —
- Price / cash flow
- -1.98x
Enterprise value
- Enterprise value
- -$31.8M
- EV / sales
- —
- EV / EBITDA
- 0.34x
- EV / EBIT
- 0.33x
- Market cap
- $63.7M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Dec 1, 2025